Education
About Us
Working with TipRanks
Follow Us
Oryzon Genomics SA (ES:ORY)
BME:ORY
ORY Stock Chart & Stats
Day’s Range― - ―
52-Week Range€1.40 - €3.69
Previous CloseN/A
Volume6.85K
Average Volume (3M)732.92K
Market Cap
€261.00M
Enterprise Value€188.80M
Total Cash (Recent Filing)€5.62M
Total Debt (Recent Filing)€16.21M
Price to Earnings (P/E)―
Beta0.54
Next Earnings
Oct 23, 2025EPS Estimate
-0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.00
Shares Outstanding79,887,700
10 Day Avg. Volume1,467,531
30 Day Avg. Volume732,922
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€2.50Price Target Upside-21.14% Downside
Rating ConsensusHold
Number of Analyst Covering0
Oryzon Genomics SA News
ORY FAQ
What was Oryzon Genomics SA’s price range in the past 12 months?
Oryzon Genomics SA lowest stock price was €1.40 and its highest was €3.69 in the past 12 months.
What is Oryzon Genomics SA’s market cap?
Oryzon Genomics SA’s market cap is €261.00M.
When is Oryzon Genomics SA’s upcoming earnings report date?
Oryzon Genomics SA’s upcoming earnings report date is Oct 23, 2025 which is in 26 days.
How were Oryzon Genomics SA’s earnings last quarter?
Oryzon Genomics SA released its earnings results on Jul 30, 2025. The company reported €0 earnings per share for the quarter, beating the consensus estimate of -€0.027 by €0.027.
Is Oryzon Genomics SA overvalued?
According to Wall Street analysts Oryzon Genomics SA’s price is currently Overvalued.
Does Oryzon Genomics SA pay dividends?
Oryzon Genomics SA does not currently pay dividends.
What is Oryzon Genomics SA’s EPS estimate?
Oryzon Genomics SA’s EPS estimate is -0.03.
How many shares outstanding does Oryzon Genomics SA have?
Oryzon Genomics SA has 79,887,700 shares outstanding.
What happened to Oryzon Genomics SA’s price movement after its last earnings report?
Oryzon Genomics SA reported an EPS of €0 in its last earnings report, beating expectations of -€0.027. Following the earnings report the stock price went down -1.476%.
Which hedge fund is a major shareholder of Oryzon Genomics SA?
Currently, no hedge funds are holding shares in ES:ORY
Company Description
Oryzon Genomics SA
Oryzon Genomics SA (ORY) is a clinical-stage biopharmaceutical company based in Spain, specializing in the development of epigenetics-based therapeutics for the treatment of diseases with strong unmet medical needs. The company operates primarily in the biotechnology and pharmaceutical sectors, focusing on the development of drugs targeting histone demethylases, a key component in the regulation of gene expression. Oryzon's core products include its lead compounds iadademstat and vafidemstat, which are being investigated for the treatment of various oncology and central nervous system disorders, respectively.
Technical Analysis
LABORATORIO REIG JOFRE
―
Laboratorios Farmaceuticos Rovi
―
Pharma Mar SA
―
ADL Bionatur Solutions SA
―
Atrys Health SA
―
Options Prices
Currently, No data available
---